Compare DBI & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBI | OABI |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 294.3M |
| IPO Year | 2005 | 2021 |
| Metric | DBI | OABI |
|---|---|---|
| Price | $5.23 | $4.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $6.75 | $4.50 |
| AVG Volume (30 Days) | 452.7K | ★ 2.1M |
| Earning Date | 06-09-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ 15.00 | 6.56 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,892,671,000.00 | $18,666,000.00 |
| Revenue This Year | $1.29 | $52.42 |
| Revenue Next Year | $1.88 | $64.69 |
| P/E Ratio | $260.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.11 | $1.32 |
| 52 Week High | $9.17 | $5.43 |
| Indicator | DBI | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 52.30 |
| Support Level | $4.74 | $1.71 |
| Resistance Level | $8.28 | N/A |
| Average True Range (ATR) | 0.27 | 0.35 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 21.87 | 2.74 |
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in two reportable segments: the Retail segment and the Brand Portfolio segment. The Retail segment, which derives key revenue, operates the DSW Designer Shoe Warehouse ("DSW") banner through its direct-to-consumer stores and e-commerce sites in the United States ("U.S.") and Canada, and the Shoe Co. and Rubino banners through its direct-to-consumer stores and e-commerce sites in Canada. The Brand Portfolio segment principally earns revenue from the wholesale of its exclusive and licensed brands to retailers, its Retail segment, and international distributors, and the sale of its Vince Camuto, Keds, and Topo brands through direct-to-consumer e-commerce sites.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.